Safety evaluation of chronic intrathecal administration of idursulfase-IT in cynomolgus monkeys

Toxicologic Pathology

Volumn 39, Issue 5, 2011, Pages 879-892

  Felice, Brian R ^a   Wright, Teresa L ^a   Boyd, Robert B ^b   Butt, Mark T ^c   Pfeifer, Richard W ^a   Pan, Jing ^a   Ruiz, Juan A ^a   Heartlein, Michael W ^a   Calias, Pericles ^a  

^a Shire Human Genetic Therapies Inc   (United States)

^b Northern Biomedical Research Inc   (United States)

^c Tox Path Specialists   (United States)

Author keywords

cynomolgus monkey; Hunter syndrome; iduronate sulfatase; idursulfase; intrathecal; lysosomal storage disease; mucopolysaccharidosis II

Indexed keywords

IDURONATE 2 SULFATASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BRAIN CELL; CELL INFILTRATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SAFETY; ENZYME ACTIVITY; HAPLORHINI; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD;

ANIMALS; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME REPLACEMENT THERAPY; IDURONATE SULFATASE; IMMUNOHISTOCHEMISTRY; INFUSION PUMPS, IMPLANTABLE; INJECTIONS, SPINAL; MACACA FASCICULARIS; MALE; MENINGES; NO-OBSERVED-ADVERSE-EFFECT LEVEL;

ANIMALIA; MACACA FASCICULARIS;

EID: 79961071835     PISSN: 01926233     EISSN: 15331601     Source Type: Journal    
DOI: 10.1177/0192623311409595     Document Type: Article

References (34)

1. Auclair D., Finnie J., White J., Nielsen T., Fuller M., Kakkis E., Cheng A., O'Neill C. A., Hopwood J. J. Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen. Mol Genet Metab. 2010 ; 99: 132-41
2. Bembi B., Ciana G., Bottega M., Pelos G., Gornati R., Berra B. Cerebrospinal fluid infusion of alglucerase in the treatment of acute neuronopathic Gaucher's disease [abstract]. Pediatr Res. 1995 ; 38: 425
3. Butt M. T. Morphologic changes associated with intrathecal catheters for direct delivery to the central nervous system in preclinical studies. Toxicol Pathol. 2011 ; 39: 213-19
4. Davson H., Segal M. B. Physiology of the CSF and Blood Brain Barriers. Boca Raton, FL: CRC Press ; 1996 :
5. Dickson P., McEntee M., Vogler C., Le S., Levy B., Peinovich M., Hanson S., Passage M., Kakkis E. Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab. 2007 ; 91: 61-68 (Pubitemid 46550919)
6. Garcia A. R., DaCosta J. M., Pan J., Muenzer J., Lamsa J. C. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II. Mol Genet Metab. 2007 ; 91: 183-90 (Pubitemid 46765176)
7. Garcia A. R., Pan J., Lamsa J. C., Muenzer J. The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome). J Inherit Metab Dis. 2007 ; 30: 924-34 (Pubitemid 350263133)
8. Grubb J. H., Vogler C., Levy B., Galvin N., Tan Y., Sly W. S. Chemically modified beta-glucuronidase crosses blood-brain barrier and clears neuronal storage in murine mucopolysaccharidosis VII. Proc Natl Acad Sci U S A. 2008 ; 105: 2616-21 (Pubitemid 351520562)
9. Hemsley K. M., Hopwood J. J. Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases. Int J Clin Pharmacol Ther. 2009 ; 47 Suppl 1: S118-23
10. Hemsley K. M., Beard H., King B. M., Hopwood J. J. Effect of high dose, repeated intra-cerebrospinal fluid injection of sulphamidase on neuropathology in mucopolysaccharidosis type IIIA mice. Genes Brain Behav. 2008 ; 7: 740-53
11. Hemsley K. M., King B., Hopwood J. J. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Mol Genet Metab. 2007 ; 90: 313-28 (Pubitemid 46241904)
12. Hemsley K. M., Luck A. J., Crawley A. C., Hassiotis S., Beard H., King B., Rozek T., Rozaklis T., Fuller M., Hopwood J. J. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. Eur J Neurosci. 2009 ; 29: 1197-214
13. Hemsley K. M., Norman E. J., Crawley A. C., Auclair D., King B., Fuller M., Lang D. L., Dean C. J., Jolly R. D., Hopwood J. J. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs-a proof of principle study. Mol Genet Metab. 2009 ; 98: 383-92
14. Hovland D. N., Boyd R. B., Butt M. T., Engelhardt J. A., Moxness M. S., Ma M. H., Emery M. G., Ernst N. B., Reed R. P., Zeller J. R., Gash D. M., Masterman D. M., Potter B. M., Cosenza M. E., Lightfoot R. M. Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys. Toxicol Pathol. 2007 ; 35: 1013-29
15. Kakkis E., McEntee M., Vogler C., Le S., Levy B., Belichenko P., Mobley W., Dickson P., Hanson S., Passage M. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab. 2004 ; 83: 163-74 (Pubitemid 39328075)
16. Kakkis E. D. Enzyme replacement therapy for the mucopolysaccharide storage disorders. Expert Opin Investig Drugs. 2002 ; 11: 675-85 (Pubitemid 34520617)
17. McVie-Wylie A. J., Lee K. L., Qiu H., Jin X., Do H., Gotschall R., Thurberg B. L., Rogers C., Raben N., O'Callaghan M., Canfield W., Andrews L., McPherson J. M., Mattaliano R. J. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol Genet Metab. 2008 ; 94: 448-55
18. Meikle P. J., Hopwood J. J., Clague A. E., Carey W. F. Prevalence of lysosomal storage disorders. JAMA. 1999 ; 281: 249-54 (Pubitemid 29058114)
19. Muenzer J., Wraith J. E., Beck M., Giugliani R., Harmatz P., Eng C. M., Vellodi A., Martin R., Ramaswami U., Gucsavas-Calikoglu M., Vijayaraghavan S., Wendt S., Puga A. C., Ulbrich B., Shinawi M., Cleary M., Piper D., Conway A. M., Kimura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet Med. 2006 ; 8: 465-73
20. Muñoz-Rojas M. V., Horovitz D. D., Jardim L. B., Raymundo M., Llerena J. C., de Magalhaes Tde S., Vieira T. A., Costa R., Kakkis E., Giugliani R. Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis. Mol Genet Metab. 2010 ; 99: 346-50
21. Muñoz-Rojas M. V., Vieira T., Costa R., Fagondes S., John A., Jardim L. B., Vedolin L. M., Raymundo M., Dickson P. I., Kakkis E., Giugliani R. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet. 2008 ; 146A: 2538-44
22. Neufeld E. F., Muenzer J. The Metabolic and Molecular Bases of Inherited Disease. Scriver C., ed. New York: McGraw-Hill ; 2001: 3421-52.
23. Penn R. D., Kroin J. S., York M. M., Cedarbaum J. M. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial). Neurosurgery. 1997 ; 40: 94-99
24. Simard J. M., Kent T. A., Chen M., Tarasov K. V., Gerzanich V. Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol. 2007 ; 6: 258-68 (Pubitemid 46228081)
25. Stamatovic S. M., Keep R. F., Andjelkovic A. V. Brain endothelial cell-cell junctions: How to "open" the blood brain barrier. Curr Neuropharmacol. 2008 ; 6: 179-92
26. United States Food and Drug Administration Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Elaprase (idursulfase) injection, application no. 125151. Pharmacology Review(s); 2006. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2006/125151s0000-Elaprase- PharmR.pdf
27. Urayama A., Grubb J. H., Banks W. A., Sly W. S. Epinephrine enhances lysosomal enzyme delivery across the blood brain barrier by up-regulation of the mannose 6-phosphate receptor. Proc Natl Acad Sci U S A. 2007 ; 104: 12873-78
28. van Aerde J., Plets C., Van der Hauwaert L. Hydrocephalus in Hunter's syndrome. Acta Paediatr Belg. 1981 ; 34: 93-96
29. Vogler C., Levy B., Grubb J. H., Galvin N., Tan Y., Kakkis E., Pavloff N., Sly W. S. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci U S A. 2005 ; 102: 14777-82 (Pubitemid 41457132)
30. von Specht B. U., Geiger B., Arnon R., Passwell J., Keren G., Goldman B., Padeh B. Enzyme replacement in Tay-Sachs disease. Neurology. 1979 ; 29: 848-54
31. Yatziv S., Epstein C. J. Hunter syndrome presenting as macrocephaly and hydrocephalus. J Med Genet. 1977 ; 14: 445-47 (Pubitemid 8262660)
32. Young I.D., Harper P.S. Incidence of Hunter's Syndrome. Hum Genet. 1982 ; 60 391 :
33. Young I. D., Harper P. S. The natural history of the severe form of Hunter's syndrome: A study based on 52 cases. Dev Med Child Neurol. 1983 ; 25: 481-89 (Pubitemid 13030892)
34. Zirzow G. C., Sanchez O. A., Murray G. J., Brady R. O., Oldfield E. H. Delivery, distribution, and neuronal uptake of exogenous mannose-terminal glucocerebrosidase in the intact rat brain. Neurochem Res. 1999 ; 24: 301-5 (Pubitemid 29067974)